All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance
During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Valeria Santini, University of Florence, Florence, IT. We asked, How should we manage hypomethylating agent (HMA) failure?
How should we manage HMA failure?
Santini firstly discusses when to assess HMA failure in patients with MDS. She then provides an overview of new agents for de novo, high-risk MDS. This includes a new HMA (guadecitabine), a BCL2 inhibitor (venetoclax), and immunotherapy (magrolimab and sabatolimab). She also evaluates targeting agents (ivosidenib and enasidenib) for relapsed/refractory MDS. Santini finishes by discussing APR-246, a new agent for patients with TP53 mutations, who have the worst prognosis.
The real-world experience of venetoclax and hypomethylating agent therapy in high-risk myelodysplastic syndromes
The current standard of care for patients with high-risk myelodysplastic syndromes (MDS) is treatment with the hypomethylating agents...
Magrolimab gets FDA breakthrough therapy designation for MDS
On September 15, 2020, the FDA granted breakthrough therapy designation to magrolimab, a first-in-class anti-CD47 monoclonal antibody, to treat newly diagnosed patients with MDS.
Subscribe to get the best content related to MDS delivered to your inbox